



ASPC 2021 VIRTUAL SUMMIT on CVD Prevention

JULY 23-25

All Times are in Central Time Zone
Times are Subject to Change

Friday, July 23, 2021		
10:00 AM – 12:00 PM	CE Satellite Symposium: Saving the Hearts of Women with Prevention This is an independent CE Symposium held in conjunction with the ASPC Virtual Summit on CVD Prevention. It is not part of the official Scientific Sessions as planned by the Scientific planning committee.	
12:15 – 1:00 PM	Product Theater: Optimizing LDL-C Management in Recent MI Patients Sponsored by Amgen This is an independent Non-CE Educational activity held in conjunction with the ASPC Virtual Summit on CVD Prevention. It is not part of the official Scientific Sessions as planned by the Scientific planning committee.	James A. Underberg, MS, MD, FACPM, FASPC, FASH, FNLA

SESSION 1 Opening Session Moderator: Peter Toth, MD, PhD, FASPC		
1:30 – 1:35 PM	Overview and Welcoming Remarks & Pre Session Assessment	Peter Toth, MD, PhD, FASPC
1:35 – 2:00 PM	Keynote Lecture: Evolution of The ABC's Of Primary & Secondary Prevention of CVD	Roger Blumenthal, MD, FASPC
2:00 – 2:35 PM	Leaders in Medicine Lecture: A Glimpse into the Future- Hypertension as Cardiovascular Disease Prevention	Suzanne Oparil, MD
2:35 – 3:05 PM	New and Emerging Therapies in Lipid Management	Peter Toth, MD, PhD, FASPC
3:05 – 3:40 PM	CVD CKD DM - A Complicated Relationship With Many Strings Attached	Seth Baum, MD, FASPC
3:40 – 3:55 PM	Question & Answer Session Panel Discussion	
3:55 – 4:05 PM	Break	
SESSION 2 Early Career Presentations Moderator: Larry Sperling, MD, FASPC		
4:05 – 4:10 PM	Introductions	
4:10 – 4:25 PM	1st Place EC Research Winner: Serum copper and the risk of CVD mortality in Normal Weight, Pre-obese and Obese men in Finland	Nzechukwu Michael Isiozor, MD, MSc(PH)
4:25 – 4:45 PM	Rapid Fire Presentations: Disparities Among Race and Gender in Sustained Achievement of Goal Lipid Levels After Acute Coronary Syndrome	Max Ambrosino, DO
	Detecting Hypertension and Improving Healthy Lifestyle in African American Women Attending Community Screening Program	Waddah Malas, MD
	"Do Not Resuscitate" Orders among Hospitalized Patients with COVID-19: Evaluating Preventive Ethics Regarding Cardiopulmonary Resuscitation	Johnathan Kirupkaran, DO
	Estimated Aggregate Treatment Benefit with Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease	Robert Ariss
	Internal Medicine Resident Education and the Impact on Cardiac Rehabilitation Referral Rates in an Ambulatory Care Setting: A Pilot Study	Maggie Wang, MD
4:45-5:00 PM	Question & Answer, Voting and Winners announced	
SESSION 3 Debate: CAC vs. BioMarkers Moderator: Ann Marie Navar, MD, PhD, FASPC		
5:00-5:05 PM	Welcome and Introductions	
5:05 – 5:30 PM	Debate: CAC vs. BioMarkers	Khurram Nasir, MD, MPH, MSc, FASPC Christie Ballantyne, MD, FASPC
5:30– 5:45 PM	Question & Answer and Post-Session Assessment	
5:45-6:45 PM	Coffee & Coaching with ASPC's Women in Preventive Cardiology Working Group	
7:30 – 9:00 PM	CE/CME Satellite Symposium: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing Cardiovascular Disease & CV Risk This is an independent CE Symposium held in conjunction with the ASPC Virtual Summit on CVD Prevention. It is not part of the official Scientific Sessions as planned by the planning committee.	

Saturday, July 24, 2021

7:45-8:30 AM CT	Product Theater: EVKEEZA® (evinacumab-dgnb) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) Sponsored by Regeneron Pharmaceuticals, Inc. This is an independent Non-CE Educational activity held in conjunction with the ASPC Virtual Summit on CVD Prevention. It is not part of the official Scientific Sessions as planned by the Scientific planning committee.	Seth J. Baum, MD, FASPC
Session 4	Ischemic Heart Disease	Moderator: David Maron, MD, FASPC
9:00 – 9:05 AM	Overview and Welcome & Pre-Session Assessment	
9:05 – 9:30 AM	Management and Prevention of ACS Events in Patients with COVID-19	Amit Khera, MD, MSc, FASPC
9:30– 9:55 AM	Ischemic Heart Disease Without Obstructive Coronary Arteries	Martha Gulati, MD, MS, FASPC
9:55– 10:15 AM	Chest Pain & Imaging	Ron Blankstein, MD, FASPC
10:15 – 10:45 AM	Question and Answer Panel Discussion & Post Assessment	
10:45 – 11:10 AM	Break	
SESSION 5	The Great Diet Debate	Moderator: Martha Gulati, MD, MS, FASPC
11:10 – 11:15 AM	Introductions & Pre-Session Assessment	Martha Gulati, MD, MS, FASPC
11:15 – 11:20 AM	Mediterranean Diet	Tracy Severson, RD, LD
11:20 – 11:25 AM	Plant Based Diet	Danielle Belardo, MD, FASPC
11:25 – 11:30 AM	South Beach Diet	Arthur Agatston, MD, FASPC
11:30 – 11:35 AM	Keto Diet	Carol Kirkpatrick, PhD, MPH, RDN
11:35 – 11:45 AM	Rebuttals	
11:45– 12:10 PM	Question and Answer Panel Discussion & Post Session Assessment	
12:10 – 1:20 PM	Lunch	
12:25 – 1:10 PM	Product Theater: Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C Sponsored by Esperion Therapeutics, Inc. This is an independent Non-CE Educational activity held in conjunction with the ASPC Virtual Summit on CVD Prevention. It is not part of the official Scientific Sessions as planned by the Scientific planning committee.	Howard Weintraub, MD, FASPC
12:25 – 1:10 PM	Product Theater: What You Need to Know About Lp(a) With Cardiovascular Disease "The Interconnected Risk" Sponsored by: Kaneka Medical America, LLC	Tina Khan PhD, MRCP, MBChB, BHB; Iftikhar J. Kullo, M.D.; Kathleen H. Byrne, M.S.N., C.R.N.P., C.C.R.N.
SESSION 6	Nanette Wenger, MD Award and Lectureship	Moderator: Heather Johnson, MD, FASPC
1:20 – 1:23 PM	Pre-Session Assessment & Introduction	
1:23 – 2:00 PM	Nanette Wenger, MD Award Lecture: How VITAL are Vitamin D and Omega-3s for Cardiometabolic Health?	JoAnn Manson, MD, DrPH, MPH
2:00– 2:10 PM	Question and Answer Panel Discussion & Post Session Assessment	
SESSION 7	Honorary Fellowship Award and Lectureship	Moderator: Amit Khera, MD, MSc, FASPC
2:10 – 2:15 PM	Introduction & Pre-Session Assessment	
2:15 – 2:45 PM	Honorary Fellowship Lecture: A New Kind of Prevention - Reducing Cardiovascular Health Disparities at the Community and Individual Level	Clyde Yancy, MD, MSc, FASPC
2:45 – 2:55 PM	Answer Panel Discussion	
2:55 – 3:05 PM	ASPC Annual Business meeting	
3:05 – 3:15 PM	Yoga Break with Nancy Cushman	
SESSION 8	Working in Prevention	Moderator: Alison Bailey, MD, FASPC
3:15 – 3:16 PM	Introductions & Pre-Session Assessment	
3:16 – 3:40 PM	Preventing Heart Failure	Javed Butler, MD, MPH, MBA
3:40 – 4:15 PM	Preventing Atrial Fibrillation	Icilma Fergus, MD
4:15 – 4:40 PM	Peripheral Artery Disease: Evaluation, Treatment, and Management	Marc Bonaca, MD, MPH
4:40– 4:55 PM	Question and Answer Panel Discussion	
4:55– 5:10 PM	Break	

SESSION 9		
Practical Applications of New Prevention Therapies		Moderator: Michael Shapiro, DO, FASPC
5:10 – 5:20 PM	Case Study Presentation & Pre Session Assessment	Michael Shapiro, DO, FASPC
5:20 – 5:25 PM	PCSK9i Discussion	Ann Marie Navar, MD, PhD, FASPC
5:25 – 5:35 PM	Practical Applications in New Prevention Therapies: Icosapent Ethyl	Heather Johnson, MD, FASPC
5:35 – 5:40 PM	SGLT2i Discussion	Alison Bailey, MD, FASPC
5:40 – 5:45 PM	GLP1 RA Discussion	Harold Bays, MD, FASPC
5:45 – 5:50 PM	Rivaroxaban Discussion	Erin Michos, MD, MHS, FASPC
5:50 – 6:10 PM	Question & Answer Panel Discussion & Post-Session Assessment	

Sunday, July 25, 2021

SESSION 10		
Practical Strategies in Practice		Moderator: Ty Gluckman, MD, FASPC
9:00 – 9:02 AM	Overview and Welcoming Remarks	
9:02 – 9:25 AM	Implementation Strategies to Improve Care: The Power of Team Based Care	Athena Poppas, MD
9:25 – 9:50 AM	Telehealth - New Billing and Practical Usage	Ami Bhatt, MD
9:50 – 10:20 AM	Technologies and Wearables	Seth Martin, MD, MHS, FASPC
10:20 – 10:40 AM	Question & Answer Panel Discussion	
SESSION 11		
Joseph Stokes III, MD Award and Lectureship		Moderator: Erin Michos, MD, MHS, FASPC
10:40 – 10:43 AM	Pre-Session Assessment & Introduction	
10:43 – 11:20 AM	Joseph Stokes III, MD, Award Lecture: Evolution of Preventive Cardiology - Framingham and Beyond	Nathan Wong, PhD, MPH, FASPC
11:20 – 11:30 AM	Post-Session Assessment and Question & Answer Panel Discussion	
11:30 AM – 12:45 PM	Break	
11:45 – 12:30 PM	Product Theater: Atherosclerotic Cardiovascular Disease (ASCVD) High Risk Assessment, Evaluation, and Management Sponsored by Novartis Pharmaceuticals Corporation <small>This is an independent Non-CE Educational activity held in conjunction with the ASCP Virtual Summit on CVD Prevention. It is not part of the official Scientific Sessions as planned by the Scientific planning committee.</small>	Guy Mintz, MD
SESSION 12		
Special Populations		Moderator: Keith Ferdinand, MD, FASPC
12:45 – 12:47 PM	Introductions & Pre-Session Assessment	
12:47 – 1:15 PM	Impact of Hormone Replacement on CVD in the Transgender Patient	Chrisandra Shufelt, MD, MS
1:15 – 1:40 PM	Physical Disabilities - Focus on Risk Assessment, Diet, Accessibility - How To Overcome Unique Challenges	Pam Taub, MD, FASPC
1:40 – 2:15 PM	Myocardial Infarction and Heart Failure among People with HIV: Risks, Mechanisms, and Preventive Approaches	Markella Zanni, MD
2:15 – 2:45 PM	Cardiovascular Risk Heterogeneity among Men and Women of South Asian Ancestry	Miguel Cainzos-Achirica, MD, MPH, PhD
2:45 – 3:05 PM	Question and answer Panel Discussion & Post Session Assessment	
3:05 PM	Wrap Up and Adjourn	Martha Gulati, MD, MS, FASPC